Unknown

Dataset Information

0

Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.


ABSTRACT:

Introduction

We prospectively tested in a phase II study high-dose aracytin and idarubicin plus amifostine as induction regimen in 149 patients with acute myeloid leukaemia (AML) aged ≥ 60 years, evaluated by a simplified multidimensional geriatric assessment (MGA).

Methods

Ninety-one fully or partially fit patients (61%) were allocated to intensive chemotherapy and 58 (39%) frail patients to best supportive care (BSC). Intensively treated patients, showing early death and complete response (CR) rate respectively of 5.5% and 73.6%, received 61 consolidations, followed by autologous transplant (ASCT), stem cell transplantation (SCT) or gemtuzumab ozogamicin, depending on mobilization outcome and donor availability.

Results

The 8-year overall survival (OS) of these patients was 20.4%, with median duration of 11.4 months significantly superior to the 1.5 months of BSC arm (p < 0.001). Hyperleukocytosis and cytogenetics were predictors of survival with a relative risk of 1.8 in patients with poor karyotype without hyperleukocytosis (p = 0.02) and 3 in those with hyperleukocytosis (≥ 50,000/μl) (p = 0.002).

Conclusion

MGA allowed tailored post-consolidation in 53.8% of patients after high-dose aracytin induction, with long-term survival doubling that reported in the literature after standard-dose cytarabine regimens.

Trial registration

The study was registered with the Umin Clinical Trial Registry (www.umin.ac.jp/ctr), number R000014052.

SUBMITTER: Capelli D 

PROVIDER: S-EPMC7467471 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.

Capelli Debora D   Saraceni Francesco F   Fiorentini Alessandro A   Chiarucci Martina M   Menotti Diego D   Poloni Antonella A   Discepoli Giancarlo G   Leoni Pietro P   Olivieri Attilio A  

Advances in therapy 20200415 5


<h4>Introduction</h4>We prospectively tested in a phase II study high-dose aracytin and idarubicin plus amifostine as induction regimen in 149 patients with acute myeloid leukaemia (AML) aged ≥ 60 years, evaluated by a simplified multidimensional geriatric assessment (MGA).<h4>Methods</h4>Ninety-one fully or partially fit patients (61%) were allocated to intensive chemotherapy and 58 (39%) frail patients to best supportive care (BSC). Intensively treated patients, showing early death and complet  ...[more]

Similar Datasets

| S-EPMC3360906 | biostudies-literature
| S-EPMC10727094 | biostudies-literature
| S-EPMC6768541 | biostudies-literature
| S-EPMC11416634 | biostudies-literature
| S-EPMC8095142 | biostudies-literature
| S-EPMC9092400 | biostudies-literature
| 2296208 | ecrin-mdr-crc
| S-EPMC11541689 | biostudies-literature
| S-EPMC10076778 | biostudies-literature
| S-EPMC10807600 | biostudies-literature